Literature DB >> 20149229

A mouse model for the Sézary syndrome.

Udo Doebbeling1.   

Abstract

BACKGROUND: The Sézary syndrome is an aggressive leukemic form of cutaneous T cell lymphoma and there is no cure of this disease. Until now there is no true animal model for Sézary syndrome, by which new drugs against the disease could be tested.
METHODS: Immune deficient CB-17 SCID beige mice were injected subcutaneously with HUT78 cells, a cell line, derived from a Sézary syndrome patient. Developing tumors were analyzed by immunohistochemistry.
RESULTS: Injected HUT78 cells formed tumors at the site of injection. In contrast to the Sézary syndrome in man, no malignant cells were observed in the blood of tumor bearing CB-17 SCID beige mice. The tumors appeared 44-62 days after injection and tumor bearing mice survived further 25 - 62 days until they had to be euthanized according to the guidelines of the Swiss animal protection law, since the tumors had reached the maximal allowed size.
CONCLUSION: Although the mouse model does not exactly match the human disease, it will be suited for tests of new substances for the treatment of the Sézary syndrome. The formation of an isolated tumor on the skin has the advantage that the effect of a potential drug can be directly monitored without the use of invasive methods.

Entities:  

Mesh:

Year:  2010        PMID: 20149229      PMCID: PMC2845106          DOI: 10.1186/1756-9966-29-11

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  15 in total

Review 1.  Cutaneous T-cell lymphoma: pathogenesis and treatment.

Authors:  M Girardi; R L Edelson
Journal:  Oncology (Williston Park)       Date:  2000-07       Impact factor: 2.990

2.  Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells.

Authors:  J Z Qin; R Dummer; G Burg; U Döbbeling
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

3.  Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.

Authors:  J Z Qin; C L Zhang; J Kamarashev; R Dummer; G Burg; U Döbbeling
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

4.  Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.

Authors:  H S Zackheim; E H Epstein; W R Crain
Journal:  J Am Acad Dermatol       Date:  1990-05       Impact factor: 11.527

5.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Authors:  Asahi Ito; Takashi Ishida; Hiroki Yano; Atsushi Inagaki; Susumu Suzuki; Fumihiko Sato; Hisashi Takino; Fumiko Mori; Masaki Ri; Shigeru Kusumoto; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

6.  Interleukin-7 is a growth factor for Sézary lymphoma cells.

Authors:  A Dalloul; L Laroche; M Bagot; M D Mossalayi; C Fourcade; D J Thacker; D E Hogge; H Merle-Béral; P Debré; C Schmitt
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?

Authors:  A H Sarris; T Esgleyes-Ribot; M Crow; H E Broxmeyer; N Karasavvas; W Pugh; D Grossman; A Deisseroth; M Duvic
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

8.  Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID mice.

Authors:  M R Charley; M Tharp; J Locker; J S Deng; J B Goslen; T Mauro; P McCoy; E Abell; B Jegasothy
Journal:  J Invest Dermatol       Date:  1990-03       Impact factor: 8.551

9.  Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells.

Authors:  U Döbbeling; R Dummer; E Laine; N Potoczna; J Z Qin; G Burg
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

10.  Establishment of a mouse xenograft model for mycosis fungoides.

Authors:  Sonja Thaler; Angelika M Burger; Thomas Schulz; Boris Brill; Alexandra Bittner; Patrick A Oberholzer; Reinhard Dummer; Barbara S Schnierle
Journal:  Exp Dermatol       Date:  2004-07       Impact factor: 3.960

View more
  3 in total

Review 1.  Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.

Authors:  Raman Preet Kaur Gill; Jennifer Gantchev; Amelia Martínez Villarreal; Brandon Ramchatesingh; Elena Netchiporouk; Oleg E Akilov; Niels Ødum; Robert Gniadecki; Sergei B Koralov; Ivan V Litvinov
Journal:  Cells       Date:  2022-02-09       Impact factor: 6.600

2.  Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.

Authors:  Martina Prochazkova-Carlotti; Floriane Cherrier; Audrey Gros; Sandrine Poglio; Elodie Laharanne; Anne Pham-Ledard; Marie Beylot-Barry; Jean-Philippe Merlio
Journal:  Leukemia       Date:  2020-10-26       Impact factor: 11.528

3.  Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro.

Authors:  Catalina Silva-Hirschberg; Hannah Hartman; Samantha Stack; Steve Swenson; Radu O Minea; Michael A Davitz; Thomas C Chen; Axel H Schönthal
Journal:  Ther Adv Med Oncol       Date:  2019-12-06       Impact factor: 8.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.